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Oxandrolone in trauma patients

!

Jane M. Gervasio, Roland N. Dickerson, Jessica Swearingen, Mary E.D. Yates, Ceaminia Yuen,
Timothy C. Fabian, Martin A. Croce, Rex O. Brown

!
Abstract
!

Study Objective
To determine the effect of oxandrolone administration on nutritional and clinical outcomes after
multiple trauma.

!

Design
Prospective, randomized, double-blind, placebo-controlled study. Setting. Level 1 trauma center
in a university teaching hospital.
Patients
Sixty-two patients requiring enteral nutrition, 60 of whom completed the study.
Intervention
Patients were randomized to receive either oxandrolone 10 mg or placebo twice/day for a
maximum of 28 days.
Measurements and Main Results
Total urinary nitrogen, prealbumin, nitrogen balance, total body water, and body cell mass were
measured on day 1 of enteral nutrition and then at day 7, day 10, and study exit. Patients were
assessed daily for metabolic and infectious complications. The two groups were similar for
demographics and dosage of enteral nutrition. Measurement of total urinary nitrogen at study
entry showed both groups to be highly catabolic (oxandrolone 17.2 ± 4.9, placebo 19.1 ± 10.8 g/
day, NS). On days 7 and 10, total urinary nitrogen increased in both groups; however, there was
no significant difference between groups. Nitrogen balance was negative throughout the study in
each group. Body cell mass decreased slightly in both groups over the study period. Prealbumin
serum concentrations increased significantly in both groups at day 10 and study exit compared
with study entry. The groups did not differ significantly for length of hospital stay (oxandrolone
30.8 ± 17.9, placebo 27.0 ± 25.7 days), length of intensive care unit stay (oxandrolone 17.1 ±
7.8, placebo 15.5 ± 9.7 days), and frequency of pneumonia or sepsis (oxandrolone 48, placebo 43
episodes).

!

Conclusion
Oxandrolone 20 mg/day does not have obvious benefit in nutritional and clinical outcomes
during the first month after multiple trauma.

!
!
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The catabolic response to injury is associated with elevated glucocorticoid, catecholamine, and
glucagon serum concentrations and a breakdown of body protein. Critical injury causes
hypermetabolism and hypercatabolism, resulting in an increase in resting energy expenditure and
decrease in body cell mass.1 Patients sustaining major trauma had a mean body protein loss of
1.62 kg (16%) over 21 days, with skeletal muscle accounting for the largest percentage.1
Specialized nutrition support (parenteral, enteral) is given to these patients to minimize this
protein loss. Quantities as high as 2–3 g/kg/day of protein have been administered in attempts to
produce net anabolism.2 Although specialized nutrition support improves the quality of patient
care, it fails to ameliorate net protein catabolism.3 Anabolic agents have been investigated for
their use in preserving body cell mass and improving muscle strength. Studies in trauma and
thermally injured patients reported improved nitrogen retention and restored muscle mass, but
therapy was limited by androgenic complications.4,5

!

Oxandrolone is a testosterone analog with reported anabolic activity 5–10 times that of older
anabolic agents and with considerably fewer androgenic effects. It improved body cell mass in
thermally injured patients during the recovery phase6 and restored muscle mass in patients with
acquired immunodeficiency syndrome.7,8 To our knowledge, no study has investigated
oxandrolone during the acute phase of injury in trauma patients. We examined the agent’s effects
on nutritional and clinical outcomes after multiple trauma.

!
!

Methods

This was a prospective, double-blinded, randomized, placebo-controlled study conducted in a
level 1 trauma center. It was approved by a university investigational review board and the
hospital. Written informed consent was obtained from all patients. A total of 62 patients with
multiple trauma requiring enteral nutrition were randomized by a table of random numbers to
receive either oxandrolone (Oxandren; BTG Corporation, Iselin, NJ) 10 mg twice/day
(maximum approved dosage for catabolic patients) or placebo. Patients had to be 18–60 years of
age, have sustained multiple trauma, and require enteral nutrition. Those who were less than 90%
of ideal body weight were considered undernourished and those more than 30% of ideal body
weight were considered obese. Exclusion criteria were renal insufficiency or failure defined by a
serum creatinine concentration above 2 mg/dl; hepatic insufficiency defined by a total bilirubin
concentration above 3 mg/dl, or cirrhosis by history or biopsy; gastrointestinal malabsorptive
disorders, metastatic carcinoma, diabetes mellitus, or human immunovirus (HIV) infection;
hypersensitivity to anabolic steroids; and pregnancy.

!

Injury Severity9 and Trauma10 scores were calculated at hospital admission. Acute Physiology
and Chronic Health Evaluation II (APACHE II)11 and Glascow Coma Scale12 scores were
calculated for each patient within the first 24 hours of entering the study. Study entry occurred
within the first five days after trauma.

!

Patients received oxandrolone or placebo for 28 days unless they were discharged or transferred
to another facility, in which case the drug was discontinued. Oxandrolone tablets or placebo
!2

tablets (thiamine 50 mg) were crushed and suspended in water before administration through a
nasogastric feeding tube or enterostomy. Patients received tablets orally when they were able to
consume an oral diet. Compliance with therapy was recorded every day.

!

Enteral nutrition was administered to each group as an immune-enhancing formula (ImmunAid;
McGaw Laboratories, Santa Ana, CA) to provide 30 total calories/kg/day and 2.4 g protein/kg/
day while in the intensive care unit (ICU). All patients who were transferred out of the ICU were
changed to a polymeric, high-protein, fiber-containing enteral formula. Oral diets were
prescribed as appropriate, and enteral nutrition was discontinued when patients were able to
consume more than 50% of required calories orally. Patients were monitored daily by the
nutrition support service for metabolic, gastrointestinal, pulmonary, and mechanical
complications. Mean daily and mean maximum caloric and protein intake were calculated for
each group.

!

Plasma electrolytes (Na+, K+, Cl-, total CO2, Ca2+, Mg2+, PO43-), blood urea nitrogen (BUN),
creatinine, prealbumin, albumin, aspartate aminotransferase (AST), total bilirubin, and alkaline
phosphatase were measured at study admission and days 7, 10, and 28, or study exit if before day
28. Twenty-four-hour urine samples were collected at study admission and days 7, 10, and 28 or
study exit for total urinary nitrogen (TUN). A 10-ml aliquot was obtained from the 24-hour urine
collection and immediately frozen at -20°C. Total urinary nitrogen was determined by
pyrochemilumenescence.

!

Total body water, lean body mass, and body cell mass were calculated by bioelectrical
impedance analysis on the same schedule. Computerized Bioelectrical Analyzer System (RJL
System, Inc., Detroit, MI) was used as described previously.13,14

!

Clinical outcome variables including length of ICU stay, hospital stay, and mechanical
ventilation days were recorded. Patients were assessed daily for infectious complications.
Infections were determined based on set criteria and defined as pneumonia by bronchial alveolar
lavage with 105 or more colony-forming units/ml15; sepsis, severe sepsis, septic shock, acute
respiratory distress syndrome (ARDS), multiple organ dysfunction syndrome (MODS), and
systemic inflammatory response syndrome (SIRS) by the American College of Chest
Physicians–Society of Critical Care Medicine consensus statement16; abdominal infections
including intraabdominal abscess, necrotizing fasciitis, and peritonitis by positive abdominal
infection and physical diagnosis; and sinusitis by mucosal thickening, computerized tomographic
scan, and positive cultures. Infections were verified and documented by a trauma surgical
physician who was blinded to study therapy.

!
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Statistical Analysis

A sample of 30 in each group was estimated to observe a decrease in TUN of 20% from baseline
to day 7 of the study in patients receiving oxandrolone, with β of 0.8 and α of 0.05. Continuous
data were analyzed by analysis of variance (ANOVA) with Tukey’s test for post hoc pairwise
!3

Table 1. Summary of Group Demographics
Age (yrs)
M/F
Height (cm)
Weight (kg)
Ideal body weight (%)
APACHE II score
Injury Severity score
Trauma score
Glasgow Coma Scale score
Trauma (blunt/penetrating)

Oxandrolone (n=30)

Placebo (n=30)

33.9 ± 12.5
26/4
177.3 ± 6.4
83.2 ± 19.4
112 ± 22
15.8 ± 5.8
27.8 ± 11.3
8.2 ± 3.5
8.9 ± 5.2
24/6

35.2 ± 11.0
29/1
179.1 ± 9.6
83.0 ± 18.7
110 ± 19
15.5 ± 5.5
25.1 ± 13.5
7.8 ± 3.4
8.3 ± 4.9
19/11

Values are expressed as mean ± SD.

!

comparisons. Categoric data were analyzed by 𝓍2 test or Fisher’s exact test. A p value less than
0.05 was considered statistically significant. All data are expressed as mean ± standard deviation
(SD).

!
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Results

Sixty-two patients were enrolled. Two who were receiving placebo withdrew, leaving 60 patients
with 30 in each group. One patient withdrew because he believed reinstitution of mechanical
ventilation was associated with the study. The other patient did not provide a reason for
withdrawal. The two groups were similar for demographics (Table 1) and administration of
specialized nutrition support (Table 2). Using admission weight and height, the oxandrolone
group consisted of 22 normally nourished, 6 obese, and 2 undernourished patients. The placebo
group had 22 normally nourished, 5 obese, 3 undernourished patients. All patients were entered
in the study within 1–5 days after injury.

!

No statistically significant differences were observed in the number of study days between the
oxandrolone and placebo group (20.3 ± 8.8 vs 18.1 ± 8.2 days, NS), and each group received
over 90% of prescribed doses of oxandrolone or placebo. In the oxandrolone group, 22 patients
were fed by small-bore nasogastric feeding tube, 2 by nasojejunal tube, 5 by jejunostomy tube,
and 1 by gastrostomy tube. Respective figures in the placebo group were 25, 1, 3, and 1. Eight
patients in the oxandrolone group and four in the placebo group required parenteral nutrition for
an average of 8 and 9 days, respectively, secondary to gastrointestinal intolerance to tube
feedings. The decision to start parenteral nutrition was made jointly between nutrition support
and trauma teams. Parenteral nutrition consisted of a formulation that was isonitrogenous and
isocaloric to the immune-enhancing enteral formula. During parenteral nutrition, oxandrolone or
placebo was given through a nasogastric tube that was clamped for 1 hour after each
administration.

!

Six patients in the oxandrolone group and five in the placebo group received propofol for
sedation or anxiety. Fat calories from propofol were calculated, and no significant differences

!
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Table 2. Nutrition Support Administration
Length of specialized nutrition support (days)
Length of enteral nutrition support (days)
Maximum calories received in 1 day (kcal/kg/day)
Maximum protein received in 1 day (g protein/kg/day)
Nitrogen intake (g/day)
Day 1
Day 7
Day 10
Day 28 or study exit
Total urinary nitrogen excretion (g/day)
Day 1
Day 7
Day 10
Day 28 or study exit
Nitrogen balance (g/day)
Day 1
Day 7
Day 10
Day 28 or study exit
Received parenteral nutrition (no.)

Oxandralone

Placebo

20.0 ± 8.7
16.4 ± 8.8
29.9 ± 10.4
2.2 ± 0.7

17.4 ± 9.3
14.6 ± 9.3
27.4 ± 8.6
2.1 ± 0.7

7.9 ± 6.2
16.5 ± 10.1
16.8 ± 12.6
16.0 ± 4.8

8.4 ± 5.8
20.6 ± 8.8
18.6 ± 10.8
12.9 ± 10.7

17.2 ± 4.8
22.2 ± 11.2
26.0 ± 11.9
16.5 ± 7.6

19.1 ± 10.8
28.0 ± 15.5
27.1 ± 5.9
18.3 ± 10.9

-11.4 ± 7.6
-9.5 ± 10.8
-11.8 ± 9.3
-3.8 ± 10.6
8

-12.8 ± 11.8
-10.9 ± 20.8
-15.1 ± 19.3
-6.3 ± 12.5
4

Values are expressed as mean ± SD.

!
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Table 3. Serum Protein Concentrations and Selected Chemistries
Serum prelbumin concentration (mg/dl)
Day 1
Day 7
Day 10
Day 28 or study exit
Serum albumin concentration (g/dl)
Day 1
Day 7
Day 10
Day 28 or study exit
Serum glucose concentration (mg/dl)
Day 1
Day 28 or study exit
Blood urea nitrogen (mg/dl)
Day 1
Day 7
Day 10
Day 28 or study exit
Serum creatinine (mg/dl)
Day 1
Day 7
Day 10
Day 28 or study exit

!

Data are expressed as mean ± SD.
ap < 0.05 compared with day 1 concentrations.
bp < 0.05 between groups.
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Oxandrolone

Placebo

11.6 ± 3.9
14.8 ± 6.2
20.9 ± 13.0a
30.5 ± 12.7a,b

10.1 ± 3.0
14.1 ± 7.0
15.8 ± 7.9a
23.0 ± 7.3a

2.3 ± 0.6
2.0 ± 0.5
2.1 ± 0.6
2.5 ± 0.6

2.2 ± 0.6
2.2 ± 0.8
2.3 ± 1.1
2.6 ± 0.6

119 ± 24
116 ± 37

133 ± 30
116 ± 25

12.4 ± 5.3
20.3 ± 14.5
28.9 ± 28
28.5 ± 40.8

13.9 ± 8.9
23.4 ± 14.6
27.7 ± 23.2
24.5 ± 18.3

0.9 ± 0.3
0.9 ± 0.5
1.1 ± 1.3
1.0 ± 1.0

0.9 ± 0.2
0.9 ± 0.2
0.9 ± 0.4
0.9 ± 0.8

were observed between patients receiving this drug in the two groups (672 ± 358 vs 674 ± 304
calories/day, NS).

!

Measurement of TUN at study entry showed both groups to be highly catabolic. On days 7 and
10, TUN increased in both groups. Mean TUN decreased by day 28 or study exit. Mean nitrogen
balance was negative on all study days in both groups. No statistically significant difference
between groups was seen for any of these values.

!

Prealbumin serum concentrations increased significantly in both groups at days 10 and study exit
compared with study entry (Table 3). The only significant difference between groups was noted
at study exit. No significant differences were appreciated with serum albumin concentrations or
serum glucose concentrations within or between groups. There were no significant differences
between groups in BUN and serum creatinine concentration. Mean BUN concentrations
approximately doubled in each group from study entrance to exit. Hepatic chemistry values in
the two groups were total bilirubin concentration (day 1, 0.9 ± 0.7 oxandrolone, 1.0 ± 0.8 g/dl
placebo; exit, 0.7 ± 0.4 vs 1.0 ± 1.0, NS), AST (day 1, 151 ± 372 vs 77 ± 102 U/ml, NS; exit, 80
± 64 vs 65 ± 41 U/ml, NS), and alkaline phosphatase (day 1, 54 ± 25 vs 49 ± 15 U/ml, NS; exit,
115 ± 117 vs 151 ± 69 U/ml, NS).

!

Body cell mass decreased slightly in each group (oxandrolone, 33.7 ± 4.6 to 31.8 ± 4.8 kg;
placebo, 32.6 ± 4.0 to 29.1 ± 3.5 kg); however, no significant differences were observed between
or within groups (Figure 1). Total body water decreased significantly (p<0.05) in each group
over the study period (oxandrolone, 58.9 ± 12.5 to 53.3 ± 14.3 L; placebo, 57.8 ± 9.6 to 47.8 ±
17.0 L). No significant differences between groups were noted in total body water at study entry
or exit (Figure 2). Complete measurements could be performed in only 15 of 60 patients
secondary to early hospital discharge or inability to measure due to metal placed on the patient
(halos, traction).

!

No significant difference were seen between groups for length of hospital stay, length of ICU
stay, and frequency of pneumonia, sepsis, ARDS, or MODS (Table 4).

!

Table 4. Clinical Outcomes
Mean ± SD length of hospital stay (days)
Mean ± SD length of ICU stay (days)
Mean ± SD length of mechanical ventilation (days)
Pneumonia (no. of patients, days)
Sepsis (no. of patients, days)
Severe sepsis (no. of patients, days)
SIRS (days)
ARDS (no. of patients)
MODS (no. of patients)
Death (no. of patients)

Oxandrolone

Placebo

30.8 ± 17.9
17.1 ± 7.8
11.7 ± 8.9
27, 170
21, 181
4, 13
283
3
2
3

27.0 ± 25.7
15.5 ± 9.7
12.6 ± 10.0
21, 129
22, 180
2, 14
243
3
1
3

SIRS = systemic inflammatory response syndome; ARDS = acute respiratory distress syndrome; MODS = multiple
organ dysfunction syndrome
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Figure 1. Body cell mass in the 15 patients (8 oxandrolone, 7 placebo) who could have bioelectrical impedance
analysis done at study entry and at day 28. There was no significant difference between or within groups over time.	


Figure 2. Total body water measurements in the 15 patients who could have bioelectrical impedance analysis done
at study entry and at day 28. Total body water decreased significantly (p<0.05) in each group over time, but there
was no significant difference between groups.

!!

!

Discussion

Oxandrolone is approved for treatment of weight loss from catabolic illness including trauma
injury. Our investigation of the approved dosage of oxandrolone in trauma patients who were
given an enteral immune-enhancing diet showed no significant differences in nutritional or
clinical outcomes compared with patients receiving placebo. Unlike this study, previous studies
in critically ill patients did not measure clinical outcome; however, our study was not specifically
powered to show a difference in clinical outcome. Also, our metabolic and nutritional findings
are in contrast to some reports4,5,17 and in agreement with others.18

!
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A prospective, randomized, double-blind study reported decreased urinary excretion of nitrogen
and 3-methylhistidine in men receiving nandrolone 50 mg on day 3 and 25 mg on day 6 after
trauma compared with similar patients receiving placebo.4 These results were supported by a
prospective, randomized study in patients who received nandrolone 50 mg 3 days after sustaining
moderate to severe head injury.17 Nitrogen balance improved in patients who received
intramuscular stanozolol 50 mg 24 hours before colorectal surgery in a prospective, randomized,
controlled trial.5 Nonseptic patients had significant improvements in body weight, lean body
mass, and body cell mass when given intramuscular nandrolone 50 mg/week.18 It is interesting
that septic patients in that prospective, randomized, unblinded study did not have significant
improvement in nutritional markers. Our patients were acutely ill from multiple trauma when
they entered the study. Virtually all had SIRS and many had sepsis during the initial weeks of the
study. Failure of the active drug to affect nutritional measurements early in the hospital course is
consistent with findings in those septic patients.18

!

All patients in the cited studies received parenteral nutrition initially. In our study, each group
received enteral nutrition initially and parenteral nutrition only when enteral intolerance was
documented. Our group and others demonstrated the clinical benefits of enteral nutrition early in
the clinical course after traumatic injury.19,20 It is also notable that all patients in our study
received an immune-enhancing enteral formulation that contained supplemental doses of
arginine, glutamine, and α-linolenic acid. Evidence indicates that clinical outcome after trauma is
improved when such formulations are administered.21-23 Whereas the number of patients and
number of days of parenteral nutrition were modestly higher in the oxandrolone group, we do not
believe that this masked improvement in clinical outcome. It may have been difficult for such
improvement to be observed in patients receiving oxandrolone because both groups primarily
were receiving enteral nutrition with an immune-enhancing diet.

!

The amount of protein administered also varied between our study and others. In previous
investigations, patients received approximately 70 g protein/day or 1 g/kg/day. This is similar to
maintenance dosages required in health (recommended daily allowance 0.8 g/kg/day in the
United States) rather than what is considered good practice in critically ill patients. Our patients
had an enteral protein goal of 2.4 g/kg/day, and a substantial number of them attained this goal
for several days.

!

Timing of anabolic steroid administration also may be an issue. Thermally injured patients given
a high protein diet plus oxandrolone had increased weight gain and improved physical therapy
index.6 That study was begun when patients began recovery in an inpatient rehabilitation center.
Another report from the same group described improved nitrogen retention during the acute
phase of thermal injury in a small number of patients.24 Patients with HIV-related weight loss
experienced restoration of body cell mass when oxandrolone was given during a program of
resistance exercise.7 These data suggest that the agent may be most beneficial when given during
the recovery phase of injury or illness. Because our study was conducted during the acute phase
after traumatic injury, our patients were definitely hypercatabolic and likely hypermetabolic,
although energy expenditure was not measured.
!8

!

The major effect of oxandrolone during short-term administration is increased net muscle protein
synthesis.25 If this is also true for acutely ill patients, it may difficult to show improved
measurements of nutrition in this population due to increased protein synthesis secondary to
critical illness and administration of an enteral diet containing nutrients such as glutamine and
arginine that also increase protein synthesis.

!

Administration of oxandrolone during the first month after multiple trauma does not result in
obvious benefit in nutritional and clinical outcomes.

!
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